-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical: RMB 2 Million in Emergency Drug Donations Arrive in Wuhan
Category:
发布时间：2020-01-31
【概要描述】
"On January 27, the third day of the Lunar New Year, 130,000 vials of emergency medicines earmarked for Wuhan’s frontline epidemic prevention and control efforts were dispatched. Among them, moxifloxacin hydrochloride sodium chloride injection valued at RMB 2 million will be donated to key hospitals in Wuhan treating pneumonia caused by the novel coronavirus infection. The donated medicines have now arrived at the hospitals without incident," said Zhu Zhiyong, Deputy General Manager of the business unit responsible for new-product development at Shijiazhuang Sihua Pharmaceutical Co., Ltd., on January 30.
"On January 27, the third day of the Lunar New Year, 130,000 vials of emergency medicines earmarked for Wuhan’s frontline epidemic prevention and control efforts were dispatched. Among them, moxifloxacin hydrochloride sodium chloride injection worth RMB 2 million will be donated to key hospitals in Wuhan treating pneumonia caused by the novel coronavirus infection. The donated medicines have now arrived at the hospitals without incident," said Zhu Zhiyong, Deputy General Manager of the business unit responsible for new-product development at Shijiazhuang Sihua Pharmaceutical Co., Ltd., on January 30.
On January 25, relevant medical institutions and state-owned pharmaceutical trading enterprises in Wuhan City requested emergency assistance from Shijiazhuang No. 4 Pharmaceutical Co., Ltd. for critical medications such as moxifloxacin hydrochloride sodium chloride injection. Upon learning of this request, Qu Jiguang, Chairman of the Board of Shijiazhuang No. 4 Pharmaceutical Group, immediately stated that the company would spare no expense to provide full support to Wuhan, allocating a portion of its production specifically for priority donation to hospitals treating COVID-19 patients. At this critical moment, saving lives must come first—there is not a moment to lose.
Staff from marketing, R&D, finance, warehousing, and logistics departments worked in close coordination to ensure the smooth outbound shipment of emergency medicines. On the afternoon of January 27, three large container trucks, loaded with 130,000 vials of moxifloxacin hydrochloride sodium chloride injection and other emergency medications destined for Wuhan, as well as donated drugs valued at RMB 2 million, sped toward Wuhan.
On the afternoon of January 27, 130,000 bottles of emergency medicines dispatched to support Wuhan’s frontline epidemic prevention and control efforts, along with saline injections containing moxifloxacin hydrochloride valued at RMB 2 million donated to key medical institutions in Wuhan, were being rapidly loaded onto trucks.
Sun Lijie, Director of the Shijiazhuang No. 4 Pharmaceutical Research Institute, who is involved in the emergency technical support effort, stated that the moxifloxacin hydrochloride and sodium chloride injection donated this time is a newly developed broad-spectrum quinolone antibacterial agent, primarily used for emergency clinical treatment in hospital respiratory departments. “This new product can play a critical role at crucial moments, which has profoundly reinforced our sense of purpose as pharmaceutical researchers. We will accelerate the development of more effective antiviral and antibacterial drugs to better safeguard public health.”
On January 27, vehicles loaded with emergency medicines to support Wuhan departed from the Shijiazhuang No. 4 Pharmaceutical plant, speeding to the front lines of epidemic prevention and control in Wuhan.
According to reports, on January 28, this batch of donated rescue medications from Shijiazhuang Sihua Pharmaceutical arrived at the designated destination in Wuhan and was promptly distributed to medical institutions as required. “Going forward, we will continue to align our efforts precisely with clinical needs, further strengthen the supply and donation of emergency medicines, and make the contribution that all employees of Shijiazhuang Sihua Pharmaceutical are committed to in order to achieve a comprehensive victory in the battle against the epidemic,” said Wu Hengyao, General Manager of Shijiazhuang Sihua Pharmaceutical.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091